RIDDLE&CODE
19.1.2021 08:10:45 CET | Business Wire | Press release
RIDDLE&CODE, an innovative European provider of secure infrastructure and technology, and Securosys, a leader in cybersecurity, encryption and digital identity protection, today announced a strategic partnership. The partnership includes the provision of Securosys HSMs for RIDDLE&CODE's Token Management Platform (TPM).
The Token Management Platform is the next generation of RIDDLE&CODE's banking-grade digital asset management solution. Operating in a secure cloud infrastructure, it delivers scalable and flexible custodial and tokenization services to the financial, energy and metal industries in Europe. Regulatory compliance has been achieved in collaboration with the Swiss financial industry.
Securosys HSMs add banking grade security features and relevant compliance processes to RIDDLE&CODE’s TMP platform.
“Our Token Management Platform is now fully interoperable with Securosys HSMs, delivering an unmatched combination of versatility and security to our customers in the energy, finance, material and mobility sectors. We are delighted to partner with Securosys and appreciate its European industry recognition and expertise. The successful deployment and integration of our software with Securosys hardware in the Swiss financial industry made this partnership a natural choice for us.” Alexander Koppel, CEO of RIDDLE&CODE.
Securosys Primus HSMs are a robust solution for securing crypto assets. Its enterprise-grade security is continuously being enhanced with additional features to protect new blockchain systems entering the market. The main advantage of HSMs is a strong security guarantee through tamper resistance and strict access controls for administrative operations.
"We are pleased to deliver our Primus HSM for Riddle&Code's Token Management Platform," said Robert Rogenmoser, CEO of Securosys. "Securosys' Blockchain HSM not only provides the best protection for private keys, but also delivers integrated multisig authentication and algorithms for distributed ledger technologies."
Riddle&Code
RIDDLE&CODE is the leading European Blockchain interface company that builds hardware and software stacks and brings trusted identity to objects and people in the financial markets, energy distribution, mobility and the Internet of Things.
Securosys SA
Securosys SA, based in Zurich, Switzerland, is a market leader in cyber security, encryption, and in securing digital identities. Founded in 2014, Securosys secures the Swiss financial markets on behalf of the Swiss National Bank and protects transactions worth over 100 billion Euros every day. The company supplies more than half of the Tier 1 banks worldwide with hardware security modules developed and built in Switzerland.
Securosys offers a wide range of security network appliances focused on commercial applications. These include communication encryption and key generation and management. All products are developed and manufactured in Switzerland, free from contaminating influences.
Further information can be obtained directly from Securosys SA by e-mail at info@securosys.ch , by calling +41 44 552 31 00, or from its offices in Zürich, Munich, and Hong Kong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom